On December 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Reporting on how deferred care worsened outcomes for patients with lung cancer during the first surge of the COVID-19 pandemic in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions keep up their appointments during the current surge. The study has been selected for the 2020 Southern Surgical Association Program and is published as an article in press in the Journal of the American College of Surgeons.
In a single-institution study reported in JCO Oncology Practice, Bernardo H.L. Goulart, MD, and colleagues found that higher out-of-pocket costs for tyrosine kinase inhibitors (TKIs) were associated with reduced adherence to and increased discontinuation of TKI therapy—as well as poorer overall survival—among patients with EGFR- and ALK-positive stage IV non–small cell lung cancer (NSCLC).
As reported in The Lancet Oncology by Goldman et al, updated results from the phase III CASPIAN trial showed maintained improvement in overall survival with first-line durvalumab plus platinum/etoposide vs platinum/etoposide in patients with extensive-stage small cell lung cancer (SCLC). However, the addition of tremelimumab to durvalumab plus platinum/etoposide did not significantly improve outcomes vs platinum/etoposide.
Although early-stage, resectable disease represents the best chance for meaningful long-term survival and cure for patients with lung cancer, there are still high rates of recurrence.